These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 31570181)

  • 1. Therapy with multi-epitope virus-like particles of B19 parvovirus reduce tumor growth and lung metastasis in an aggressive breast cancer mouse model.
    Jiménez-Chávez ÁJ; Moreno-Fierros L; Bustos-Jaimes I
    Vaccine; 2019 Nov; 37(49):7256-7268. PubMed ID: 31570181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B19-VLPs as an effective delivery system for tumour antigens to induce humoral and cellular immune responses against triple negative breast cancer.
    Jiménez-Chávez ÁJ; Nava-García BK; Bustos-Jaimes I; Moreno-Fierros L
    Immunol Lett; 2021 Nov; 239():77-87. PubMed ID: 34508790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of Breast Cancer-Related Epitopes Targeting the IGF-1 Receptor in Chimeric Human Parvovirus B19 Virus-Like Particles.
    Salazar-González JA; Ruiz-Cruz AA; Bustos-Jaimes I; Moreno-Fierros L
    Mol Biotechnol; 2019 Oct; 61(10):742-753. PubMed ID: 31317318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-helper cell-mediated interferon-gamma, interleukin-10 and proliferation responses to a candidate recombinant vaccine for human parvovirus B19.
    Franssila R; Hedman K
    Vaccine; 2004 Sep; 22(27-28):3809-15. PubMed ID: 15315862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric Virus-Like Particles and Capsomeres Induce Similar CD8
    Pattinson DJ; Apte SH; Wibowo N; Rivera-Hernandez T; Groves PL; Middelberg APJ; Doolan DL
    Front Immunol; 2020; 11():564627. PubMed ID: 33133076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T helper cell-mediated interferon-gamma expression after human parvovirus B19 infection: persisting VP2-specific and transient VP1u-specific activity.
    Franssila R; Auramo J; Modrow S; Möbs M; Oker-Blom C; Käpylä P; Söderlund-Venermo M; Hedman K
    Clin Exp Immunol; 2005 Oct; 142(1):53-61. PubMed ID: 16178856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of immune responses induced by porcine parvovirus virus-like particles and inactivated vaccine.
    Tian W; Qiu Z; Cui Y; Zhang J; Ma X; Cui S; Zheng S
    Pak J Pharm Sci; 2019 Jan; 32(1(Special)):377-382. PubMed ID: 30852473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parvovirus B19 empty capsids as antigen carriers for presentation of antigenic determinants of dengue 2 virus.
    Amexis G; Young NS
    J Infect Dis; 2006 Sep; 194(6):790-4. PubMed ID: 16941345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Murine polyomavirus virus-like particles carrying full-length human PSA protect BALB/c mice from outgrowth of a PSA expressing tumor.
    Eriksson M; Andreasson K; Weidmann J; Lundberg K; Tegerstedt K; Dalianis T; Ramqvist T
    PLoS One; 2011; 6(8):e23828. PubMed ID: 21858228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide presentation on primate erythroparvovirus 1 virus-like particles: In vitro assembly, stability and immunological properties.
    Del Carmen Morán-García A; Rivera-Toledo E; Echeverría O; Vázquez-Nin G; Gómez B; Bustos-Jaimes I
    Virus Res; 2016 Sep; 224():12-8. PubMed ID: 27523978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virus-Like Particles Presenting the FGF-2 Protein or Identified Antigenic Peptides Promoted Antitumor Immune Responses in Mice.
    Shu C; Sun P; Xie H; Huang W; Qi J; Ma Y
    Int J Nanomedicine; 2020; 15():1983-1996. PubMed ID: 32308382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy of radioresistant mammary tumors with early metastasis using molecular chaperone vaccines combined with ionizing radiation.
    Weng D; Song B; Koido S; Calderwood SK; Gong J
    J Immunol; 2013 Jul; 191(2):755-63. PubMed ID: 23772032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
    Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
    Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T lymphocyte responses against human parvovirus B19: small virus, big response.
    Klenerman P; Tolfvenstam T; Price DA; Nixon DF; Broliden K; Oxenius A
    Pathol Biol (Paris); 2002 Jun; 50(5):317-25. PubMed ID: 12116850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization with short peptide particles reveals a functional CD8
    He X; Zhou S; Dolan M; Shi Y; Wang J; Quinn B; Jahagirdar D; Huang WC; Tsuji M; Pili R; Ito F; Ortega J; Abrams SI; Ebos JML; Lovell JF
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34862254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of a parvovirus B19 vaccine candidate.
    Chandramouli S; Medina-Selby A; Coit D; Schaefer M; Spencer T; Brito LA; Zhang P; Otten G; Mandl CW; Mason PW; Dormitzer PR; Settembre EC
    Vaccine; 2013 Aug; 31(37):3872-8. PubMed ID: 23827313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Saccharomyces cerevisiae-derived virus-like particle parvovirus B19 vaccine elicits binding and neutralizing antibodies in a mouse model for sickle cell disease.
    Penkert RR; Young NS; Surman SL; Sealy RE; Rosch J; Dormitzer PR; Settembre EC; Chandramouli S; Wong S; Hankins JS; Hurwitz JL
    Vaccine; 2017 Jun; 35(29):3615-3620. PubMed ID: 28554503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Preparation of human parvovirus B19 virus-like particles].
    Zou X; Dong L; Song J; Qu J; Yu X; Lu Z; Hong T
    Sheng Wu Gong Cheng Xue Bao; 2009 Apr; 25(4):575-9. PubMed ID: 19637634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant virus-like particles presenting IL-33 successfully modify the tumor microenvironment and facilitate antitumor immunity in a model of breast cancer.
    Feng X; Liu H; Chu X; Sun P; Huang W; Liu C; Yang X; Sun W; Bai H; Ma Y
    Acta Biomater; 2019 Dec; 100():316-325. PubMed ID: 31542504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.